Nucleic Acid Therapeutics
Latest Publications

TOTAL DOCUMENTS

480

(FIVE YEARS 134)

H-INDEX

(FIVE YEARS 8)

Published By Mary Ann Liebert

2159-3345, 2159-3337

Latest Documents Most Cited Documents Contributed Authors Related Sources Related Keywords

Combining Heparin and a FX/Xa Aptamer to Reduce Thrombin Generation in Cardiopulmonary Bypass and COVID-19

Nucleic Acid Therapeutics ◽

10.1089/nat.2021.0077 ◽

2022 ◽

Author(s):

Charlene V. Chabata ◽

James W. Frederiksen ◽

Lyra B. Olson ◽

Ibtehaj A. Naqvi ◽

Sharon E. Hall ◽

...

Keyword(s):

Cardiopulmonary Bypass ◽

Thrombin Generation

Download Full-text

Individualized Antisense Oligonucleotide Therapies: How to Approach the Challenge of Manufacturing These Oligos from a Chemistry, Manufacturing, and Control-Regulatory Standpoint

Nucleic Acid Therapeutics ◽

10.1089/nat.2021.0030 ◽

2021 ◽

Author(s):

Marc M. Lemaitre

Keyword(s):

Antisense Oligonucleotide ◽

And Control

Download Full-text

Challenges and Opportunities for Nucleic Acid Therapeutics

Nucleic Acid Therapeutics ◽

10.1089/nat.2021.0085 ◽

2021 ◽

Author(s):

David R. Corey ◽

Masad J. Damha ◽

Muthiah Manoharan

Keyword(s):

Nucleic Acid ◽

Nucleic Acid Therapeutics ◽

Challenges And Opportunities

Download Full-text

Quantification of Antisense Oligonucleotides by Splint Ligation and Quantitative Polymerase Chain Reaction

Nucleic Acid Therapeutics ◽

10.1089/nat.2021.0040 ◽

2021 ◽

Author(s):

Minwook Shin ◽

Pranathi Meda Krishnamurthy ◽

Gitali Devi ◽

Jonathan K. Watts

Keyword(s):

Polymerase Chain Reaction ◽

Antisense Oligonucleotides ◽

Quantitative Polymerase Chain Reaction ◽

Chain Reaction ◽

Polymerase Chain

Download Full-text

MiRNA-Mediated Knockdown of ATXN3 Alleviates Molecular Disease Hallmarks in a Mouse Model for Spinocerebellar Ataxia Type 3

Nucleic Acid Therapeutics ◽

10.1089/nat.2021.0020 ◽

2021 ◽

Author(s):

Rui Jorge Nobre ◽

Diana D. Lobo ◽

Carina Henriques ◽

Sonia P. Duarte ◽

Sara M. Lopes ◽

...

Keyword(s):

Mouse Model ◽

Spinocerebellar Ataxia ◽

Spinocerebellar Ataxia Type ◽

Spinocerebellar Ataxia Type 3 ◽

Type 3

Download Full-text

Differential Uptake of Antisense Oligonucleotides in Mouse Hepatocytes and Macrophages Revealed by Simultaneous Two-Photon Excited Fluorescence and Coherent Raman Imaging

Nucleic Acid Therapeutics ◽

10.1089/nat.2021.0059 ◽

2021 ◽

Author(s):

Prabuddha Mukherjee ◽

Edita Aksamitiene ◽

Aneesh Alex ◽

Jindou Shi ◽

Kajari Bera ◽

...

Keyword(s):

Antisense Oligonucleotides ◽

Raman Imaging ◽

Two Photon ◽

Mouse Hepatocytes ◽

Coherent Raman

Download Full-text

Individualized Therapeutics Development for Rare Diseases: The Current Ethical Landscape and Policy Responses

Nucleic Acid Therapeutics ◽

10.1089/nat.2021.0035 ◽

2021 ◽

Author(s):

Alison Bateman-House ◽

Lisa Kearns

Keyword(s):

Rare Diseases ◽

Policy Responses ◽

Therapeutics Development

Download Full-text

CRISPR/Cas and Hepatitis B Therapy: Technological Advances and Practical Barriers

Nucleic Acid Therapeutics ◽

10.1089/nat.2021.0075 ◽

2021 ◽

Author(s):

Dmitry Kostyushev ◽

Anastasiya Kostyusheva ◽

Natalia Ponomareva ◽

Sergey Brezgin ◽

Vladimir Chulanov

Keyword(s):

Hepatitis B ◽

Technological Advances

Download Full-text

Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial

Nucleic Acid Therapeutics ◽

10.1089/nat.2021.0043 ◽

2021 ◽

Author(s):

Laurent Servais ◽

Eugenio Mercuri ◽

Volker Straub ◽

Michela Guglieri ◽

Andreea M. Seferian ◽

...

Keyword(s):

Duchenne Muscular Dystrophy ◽

Muscular Dystrophy ◽

Phase 1 ◽

Open Label ◽

Efficacy Data ◽

Safety And Efficacy ◽

Ambulatory Patients ◽

Open Label Phase

Download Full-text

Optimization of RNA Aptamer SELEX Methods: Improved Aptamer Transcript 3′-End Homogeneity, PAGE Purification Yield, and Target-Bound Aptamer RNA Recovery

Nucleic Acid Therapeutics ◽

10.1089/nat.2021.0060 ◽

2021 ◽

Author(s):

Chandan Narayan ◽

Suresh Veeramani ◽

William H. Thiel

Keyword(s):

Rna Aptamer

Download Full-text

Nucleic Acid TherapeuticsLatest Publications

TOTAL DOCUMENTS

H-INDEX

Published By Mary Ann Liebert

Combining Heparin and a FX/Xa Aptamer to Reduce Thrombin Generation in Cardiopulmonary Bypass and COVID-19

Individualized Antisense Oligonucleotide Therapies: How to Approach the Challenge of Manufacturing These Oligos from a Chemistry, Manufacturing, and Control-Regulatory Standpoint

Challenges and Opportunities for Nucleic Acid Therapeutics

Quantification of Antisense Oligonucleotides by Splint Ligation and Quantitative Polymerase Chain Reaction

MiRNA-Mediated Knockdown of ATXN3 Alleviates Molecular Disease Hallmarks in a Mouse Model for Spinocerebellar Ataxia Type 3

Differential Uptake of Antisense Oligonucleotides in Mouse Hepatocytes and Macrophages Revealed by Simultaneous Two-Photon Excited Fluorescence and Coherent Raman Imaging

Individualized Therapeutics Development for Rare Diseases: The Current Ethical Landscape and Policy Responses

CRISPR/Cas and Hepatitis B Therapy: Technological Advances and Practical Barriers

Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial

Optimization of RNA Aptamer SELEX Methods: Improved Aptamer Transcript 3′-End Homogeneity, PAGE Purification Yield, and Target-Bound Aptamer RNA Recovery

Nucleic Acid Therapeutics
Latest Publications